Completed PHASE1 INTERVENTIONAL 2-arm NCT06049966

Atezolizumab in Large Cell Neuroendocrine Carcinoma (LANCE)

Effectiveness of Atezolizumab in Large Cell Neuroendocrine Carcinoma of the Lung and the Value of miR21 and miR-375 as Biomarkers

Sponsor: Oncology Center of Biochemical Education And Research

Conditions Large Cell Neuroendocrine Carcinoma of the Lung

Interventions Atezolizumab Carboplatin Etoposide

Updated 3 times since 2023 Last updated: Sep 16, 2023 Started: Mar 1, 2018 Primary completion: Aug 1, 2022 Completion: May 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Large Cell Neuroendocrine Carcinoma of the Lung, this trial is completed. The trial is conducted by Oncology Center of Biochemical Education And Research and has accumulated 3 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Oct 2023 — Jul 2024 [monthly]

Completed PHASE1

First recorded

Mar 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Oncology Center of Biochemical Education And Research

Data source: Oncology Center of Biochemical Education And Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Athens, Greece